异氰酸3-(三氟甲基)-4-甲基苯酯 | 51903-64-1

• 物质功能分类: 化学试剂 - 有机试剂 - 氰酸酯/异氰酸酯
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 异氰酸3-(三氟甲基)-4-甲基苯酯
• 中文别名: 4-甲基-3-三氟甲基苯异氰酸酯；3-(三氟甲基)-4-甲基异氰酸苯酯
• 英文名称: 4-isocyanato-1-methyl-2-(trifluoromethyl)benzene
• 英文别名: 3-(trifluoromethyl)-4-methylphenyl isocyanate；4-methyl-3-trifluoromethylphenyl isocyanate
• CAS: 51903-64-1
• 化学式: C₉H₆F₃NO
• 分子量: 201.148
• InChiKey: XWSZWQGFJRBXMO-UHFFFAOYSA-N

物化性质

• 沸点：
  190-191 °C(lit.)
• 密度：
  1.288 g/mL at 25 °C(lit.)
• 闪点：
  175 °F
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S23,S26,S36,S45
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  2929109000
• 危险品运输编号：
  UN 2206 6.1/PG 3

反应信息

• 作为反应物：
  描述：

  6-(3-aminophenyl)-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine 、 异氰酸3-(三氟甲基)-4-甲基苯酯 以 甲苯 为溶剂， 反应 0.5h， 生成 1-(4-methyl-3-trifluoromethyl-phenyl)-3-(3-{8-[(pyridin-4-yl-methyl)-amino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-urea
  参考文献：
  名称：

  Imidazo[1,2-a]pyrazine diaryl ureas: Inhibitors of the receptor tyrosine kinase EphB4

  摘要：

  Inhibition of receptor tyrosine kinases (RTKs) such as vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) has been validated by recently launched small molecules Sutent(R) and Nexavar(R), both of which display activities against several angiogenesis-related RTKs. EphB4, a receptor tyrosine kinase (RTK) involved in the processes of embryogenesis and angiogenesis, has been shown to be aberrantly up regulated in many cancer types such as breast, lung, bladder and prostate. We propose that inhibition of EphB4 in addition to other validated RTKs would enhance the anti-angiogenic effect and ultimately result in more pronounced anti-cancer efficacy. Herein we report the discovery and SAR of a novel series of imidazo[1,2-a]pyrazine diarylureas that show nano-molar potency for the EphB4 receptor, in addition to potent activity against several other RTKs. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.037
• 作为产物：
  描述：

  三光气 、 5-氨基-2-甲基三氟甲苯 以 甲苯 为溶剂， 反应 0.5h， 生成 异氰酸3-(三氟甲基)-4-甲基苯酯
  参考文献：
  名称：

  COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF

  摘要：

  本发明提供了调节蛋白功能的化合物，以恢复蛋白稳态，包括细胞因子、CK1α、GSPT1、艾奥洛斯和/或伊卡洛斯活性和细胞间粘附。该发明提供了一种调节蛋白介导的疾病的方法，如细胞因子介导的疾病、障碍、状况或反应。提供了包括与其他细胞因子和炎症介质结合的组合物。提供了治疗、改善或预防与蛋白相关的疾病、障碍或状况的方法，包括与细胞因子相关的疾病、障碍和状况，包括炎症、纤维肌痛、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病、银屑病关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺病、慢性阻塞性肺病、阿尔茨海默病和癌症。

  公开号：

  US20180170948A1

文献信息

• Certain substituted ureas, as modulators of kinase activity
  申请人：Mitchell A. Scott

  公开号：US20060270702A1

  公开（公告）日：2006-11-30

  Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

  本文提供了从化合物1的化学实体和药用可接受的盐、溶剂化合物、螯合物、非共价复合物和前药中选择的某些化学实体。本文还提供了包括至少一种化学实体和一种或多种药用可接受载体（如载体、辅料和赋形剂）的药物组合物。公开了治疗对血管生成激酶调节敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的有效量以减少疾病或疾病症状的方法。这些疾病包括癌症，包括乳腺肿瘤、子宫内膜癌、结肠癌和颈部鳞状细胞癌。治疗方法包括将至少一种化学实体作为单一活性剂或将至少一种化学实体与一种或多种其他治疗剂结合使用的方法。一种用于确定样品中是否存在血管生成激酶的方法，包括将样品与至少一种化学实体接触在允许检测血管生成激酶活性的条件下，检测血管生成激酶活性水平，并从中确定样品中是否存在血管生成激酶。
• Substituted Pyrrolopyridines, Compositions Containing Them, Manufacturing Process Therefor and Use Thereof
  申请人：Tabart Michel

  公开号：US20080139606A1

  公开（公告）日：2008-06-12

  The invention relates to compounds of formula (I): wherein Ra, R1, Ar, L, A, W, Y, and Z are as defined in the disclosure; to compositions containing them; and to the preparation and use thereof, in particular as anticancer agents.

  该发明涉及公式（I）的化合物：其中Ra、R1、Ar、L、A、W、Y和Z如披露中定义；含有它们的组合物；以及其制备和使用，特别是作为抗癌剂。
• (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES
  申请人：Cumming John

  公开号：US20100152197A1

  公开（公告）日：2010-06-17

  The present invention relates to compounds of formula (I) The compounds act via antagonism of the CCR2b receptor and may be used to treat inflammatory disease and/or neuropathic pain.

  本发明涉及公式（I）的化合物。这些化合物通过拮抗CCR2b受体发挥作用，可用于治疗炎症性疾病和/或神经病理性疼痛。
• Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof
  申请人：RONAN Baptiste

  公开号：US20080167368A1

  公开（公告）日：2008-07-10

  The disclosure concerns substituted pyrroles of formula (I): wherein A, L, Ar, R1, R2, R5, and Ra are as defined in the disclosure, compositions containing the same, methods for making the same and uses thereof, in particular as anti-cancer agents.

  该公开涉及式(I)的取代吡咯化合物：其中A、L、Ar、R1、R2、R5和Ra如公开中定义，包含这种化合物的组合物，制备这种化合物的方法以及其用途，特别是作为抗癌剂。
• SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE
  申请人：Bjergarde Kirsten

  公开号：US20090291984A1

  公开（公告）日：2009-11-26

  The disclosure relates to a compound of formula (1): and salts thereof; wherein Ar, L, A, X, R 1 , R 2 , R 3 , R 4 a, R 4 b, and R 5 are as defined in the disclosure; compositions comprising said compounds, methods for their preparation, intermediates thereto, and the use thereof, particularly as drugs.

  该披露涉及一个式（1）的化合物及其盐；其中Ar、L、A、X、R1、R2、R3、R4a、R4b和R5如披露中定义；包含该化合物的组合物，其制备方法，中间体以及其用途，特别是作为药物。